Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2007 Jul 2;8(1):45.
doi: 10.1186/1465-9921-8-45.

Efficacy and safety of tiotropium in COPD patients in primary care--the SPiRiva Usual CarE (SPRUCE) study

Daryl Freeman  1 , Angela Lee, David Price
Affiliations
Randomized Controlled Trial

Efficacy and safety of tiotropium in COPD patients in primary care--the SPiRiva Usual CarE (SPRUCE) study

Daryl Freeman et al. Respir Res. .

Abstract

Background: Clinical trials of tiotropium have principally recruited patients from secondary care with more severe chronic obstructive pulmonary disease (COPD), and typically had included limitation of concomitant medication. In primary care, which is the most common setting for COPD management, many patients may have milder disease, and also may take a broad range of concomitant medication.

Methods: This randomised, placebo-controlled, parallel-group, 12-week, 44-centre study investigated the efficacy (trough forced expiratory volume in 1 second [FEV1] response) and safety of additional treatment with once-daily tiotropium 18 mug via the HandiHaler in a primary care COPD population (tiotropium: N = 191, FEV1 = 1.25 L [47.91% predicted]; placebo: N = 183, FEV1 = 1.32 L [49.86% predicted]). Secondary endpoints included: trough forced vital capacity (FVC) response, weekly use of rescue short-acting beta-agonist, and exacerbation of COPD (complex of respiratory symptoms/events of >3 days in duration requiring a change in treatment). Treatment effects were determined using non-parametric analysis.

Results: At Week 12, median improvement in trough FEV1 response with tiotropium versus placebo was 0.06 L (p = 0.0102). The improvement was consistent across baseline treatment and COPD severity. Median improvement in FVC at 2, 6 and 12 weeks was 0.12 L (p < 0.001). The percentage of patients with > or =1 exacerbation was reduced (tiotropium 9.5%; placebo 17.9%; p = 0.0147), independent of disease severity. Rescue medication usage was significantly reduced in the tiotropium group compared with placebo. Adverse event profile was consistent with previous studies.

Conclusion: Tiotropium provides additional benefits to usual primary care management in a representative COPD population.

Trial registration: The identifier is: NCT00274079.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Study flow.
Figure 2
Figure 2
Median changes from baseline in weekly mean number of occasions per day of rescue SABA use over 12 weeks (FAS-DIARY).
See this image and copyright information in PMC

References

    1. British Thoracic Society BTS guidelines for the management of chronic obstructive pulmonary disease. The COPD Guidelines Group of the Standards of Care Committee of the BTS. Thorax. 1997;52(suppl 5):S1–S28. - PMC - PubMed
    1. Chronic Obstructive Pulmonary Disease Management of Chronic Obstructive Pulmonary Disease in Adults in Primary and Secondary Care. NICE Clinical Guideline. 2004;12:1–53.
    1. Global Initiative for Chronic Obstructive Pulmonary Disease Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. GOLD-Global initiative for chronic obstructive lung disease. 2003. pp. 1–30. - PubMed
    1. Siafakas NM, Vermeire P, Pride NB, Paoletti P, Gibson J, Howard P, Yernault JC, Decramer M, Higenbottam T, Postma DS, et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD): ERS consensus statement. Eur Respir J. 1995;8:1398–420. doi: 10.1183/09031936.95.08081398. - DOI - PubMed
    1. Voelkel NF. Raising awareness of COPD in primary care. Chest. 2000;117(Suppl):372–375. doi: 10.1378/chest.117.5_suppl_2.372S. - DOI - PubMed

Publication types

Associated data